Patents by Inventor Danielle L. Biggs
Danielle L. Biggs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9763966Abstract: Effective treatments of pain and inflammation are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce, prevent or treat inflammation and pain and autoimmune disorders. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to reduce, prevent or treat sciatic pain and/or inflammation. In various embodiments, prevent transplant rejection for at least twenty-five days. In some embodiments, the pain relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.Type: GrantFiled: September 4, 2015Date of Patent: September 19, 2017Assignee: Warsaw Orthopedic, Inc.Inventors: William F. McKay, Christopher M Hobot, Danielle L. Biggs, Katara Shaw, John Myers Zanella, Vanja Margareta King, Stephen Mark Cox, Kathy L. Remsen
-
Patent number: 9763917Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.Type: GrantFiled: January 29, 2015Date of Patent: September 19, 2017Assignee: Warsaw Orthopedic, Inc.Inventors: John Myers Zanella, Christopher M. Hobot, Danielle L. Biggs, Katara Shaw, Phillip Edward McDonald, Vanja Margareta King, William F. McKay, Kathy L. Remsen
-
Publication number: 20170128093Abstract: Described here are paranasal sinus devices for treating paranasal sinus conditions. The devices include a cavity member, ostial member, and nasal portion. One or more of the cavity member, ostial member, and nasal portion may deliver an active agent for sustained release to treat the paranasal sinus condition. Exemplary paranasal sinus conditions are sinus inflammation due to functional endoscopic sinus surgery (FESS) and rhinosinusitis.Type: ApplicationFiled: January 25, 2017Publication date: May 11, 2017Inventors: Donald J. EATON, Thomas R. TICE, David B. DOWNIE, Patrick A. ARENSDORF, Rodney A. BRENNEMAN, Danielle L. BIGGS
-
Patent number: 9585681Abstract: Described here are paranasal sinus devices for treating paranasal sinus conditions. The devices include a cavity member, ostial member, and nasal portion. One or more of the cavity member, ostial member, and nasal portion may deliver an active agent for sustained release to treat the paranasal sinus condition. Exemplary paranasal sinus conditions are sinus inflammation due to functional endoscopic sinus surgery (FESS) and rhinosinusitis.Type: GrantFiled: September 15, 2010Date of Patent: March 7, 2017Assignee: Intersect ENT, Inc.Inventors: Donald J. Eaton, Thomas R. Tice, David B. Downie, Patrick A. Arensdorf, Rodney A. Brenneman, Danielle L. Biggs
-
Patent number: 9585872Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.Type: GrantFiled: January 29, 2015Date of Patent: March 7, 2017Assignee: Warsaw Orthopedic, Inc.Inventors: John Myers Zanella, Christopher M. Hobot, Danielle L. Biggs, Katara Shaw, Phillip Edward McDonald, Vanja Margareta King, William F. McKay, Kathy L. Remsen
-
Patent number: 9549920Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a polymer and a therapeutically effective amount of a local anesthetic or pharmaceutically acceptable salt thereof, wherein the drug depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the drug depot is capable of releasing (i) a bolus dose of the local anesthetic or pharmaceutically acceptable salt thereof at a site beneath the skin and (ii) a sustained release dose of an effective amount of the local anesthetic or pharmaceutically acceptable salt thereof over a period of at least 4 days.Type: GrantFiled: September 29, 2014Date of Patent: January 24, 2017Assignee: Warsaw Orthopedic, Inc.Inventors: Amira Wohabrebbi, William F. McKay, Vanja Margareta King, Danielle L. Biggs, Katara Shaw, Christopher Hobot, Phillip Edward McDonald
-
Patent number: 9511077Abstract: Improved medical devices and methods are provided comprising an anabolic agent for wound healing. These improved medical devices and methods can enhance wound healing in wounds from cuts, abrasions, lesions, burns including sunburn, surgical incisions, pressure ulcers, diabetic ulcers, traumatic wounds, or other injuries or maladies, which can be chronic or non-chronic in origin. In some embodiments, the medical device comprises a drug depot that releases the anabolic agent over at least 3 days to enhance wound healing.Type: GrantFiled: April 25, 2011Date of Patent: December 6, 2016Assignee: Warsaw Orthopedic, Inc.Inventors: Danielle L. Biggs, Jared T. Wilsey
-
Patent number: 9301946Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine and a gamma-aminobutyric acid compound at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.Type: GrantFiled: December 2, 2011Date of Patent: April 5, 2016Assignee: Warsaw Orthopedic, Inc.Inventors: Jared T. Wilsey, Danielle L. Biggs, Jeffrey C. Marx, William F. McKay, Josee Roy, John Myers Zanella
-
Publication number: 20160022704Abstract: Effective treatments of pain and inflammation are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce, prevent or treat inflammation and pain and autoimmune disorders. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to reduce, prevent or treat sciatic pain and/or inflammation. In various embodiments, prevent transplant rejection for at least twenty-five days. In some embodiments, the pain relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.Type: ApplicationFiled: September 4, 2015Publication date: January 28, 2016Inventors: William F. McKay, Christopher M. Hobot, Danielle L. Biggs, Katara Shaw, John Myers Zanella, Vanja Margareta King, Stephen Mark Cox, Kathy L. Remsen
-
Publication number: 20150148396Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.Type: ApplicationFiled: January 29, 2015Publication date: May 28, 2015Inventors: John Myers Zanella, Christopher M. Hobot, Danielle L. Biggs, Katara Shaw, Phillip Edward McDonald, Vanja Margareta King, William F. McKay, Kathy L. Remsen
-
Publication number: 20150148397Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.Type: ApplicationFiled: January 29, 2015Publication date: May 28, 2015Inventors: John M. Zanella, Christopher M. Hobot, Danielle L. Biggs, Katara Shaw, Phillip Edward McDonald, Vanja Margareta King, William F. McKay, Kathy L. Remsen
-
Patent number: 8946277Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.Type: GrantFiled: April 8, 2009Date of Patent: February 3, 2015Assignee: Warsaw Orthopedic, Inc.Inventors: John Myers Zanella, Christopher M. Hobot, Danielle L. Biggs, Katara Shaw, Phillip Edward McDonald, Vanja Margareta King, William F. McKay, Kathy L. Remsen
-
Publication number: 20150018390Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a polymer and a therapeutically effective amount of a local anesthetic or pharmaceutically acceptable salt thereof, wherein the drug depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the drug depot is capable of releasing (i) a bolus dose of the local anesthetic or pharmaceutically acceptable salt thereof at a site beneath the skin and (ii) a sustained release dose of an effective amount of the local anesthetic or pharmaceutically acceptable salt thereof over a period of at least 4 days.Type: ApplicationFiled: September 29, 2014Publication date: January 15, 2015Inventors: Amira Wohabrebbi, William F. McKay, Vanja Margareta King, Danielle L. Biggs, Katara Shaw, Christopher Hobot, Phillip Edward McDonald
-
Publication number: 20140324025Abstract: Described here are devices, methods, and kits for treating sinusitis and related respiratory conditions by locally delivering active agents to the osteomeatal complex over a sustained period of time. The devices may be passively fixed within the osteomeatal complex and/or include one or more features that actively fix it within the osteomeatal complex. The devices may optionally include a portion that extends into a sinus ostium, sinus cavity, and/or the nasal passage to deliver an active agent.Type: ApplicationFiled: July 9, 2014Publication date: October 30, 2014Inventors: Patrick A. ARENSDORF, Danielle L. BIGGS, Rodney BRENNEMAN, David B. DOWNIE, Donald J. EATON, Thomas R. TICE
-
Patent number: 8858974Abstract: Described here are paranasal sinus devices for treating paranasal sinus conditions. The devices include a cavity member, ostial member, and nasal portion. One or more of the cavity member, ostial member, and nasal portion may deliver an active agent for sustained release to treat the paranasal sinus condition. Exemplary paranasal sinus conditions are sinus inflammation due to functional endoscopic sinus surgery (FESS) and rhinosinusitis.Type: GrantFiled: November 13, 2008Date of Patent: October 14, 2014Assignee: Intersect ENT, Inc.Inventors: Donald J. Eaton, Thomas R. Tice, David B. Downie, Patrick A. Arensdorf, Rodney Brenneman, Danielle L. Biggs
-
Patent number: 8846068Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a polymer and a therapeutically effective amount of a local anesthetic or pharmaceutically acceptable salt thereof, wherein the drug depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the drug depot is capable of releasing (i) a bolus dose of the local anesthetic or pharmaceutically acceptable salt thereof at a site beneath the skin and (ii) a sustained release dose of an effective amount of the local anesthetic or pharmaceutically acceptable salt thereof over a period of at least 4 days.Type: GrantFiled: April 8, 2009Date of Patent: September 30, 2014Assignee: Warsaw Orthopedic, Inc.Inventors: Amira Wohabrebbi, William F. McKay, Vanja Margareta King, Danielle L. Biggs, Katara Shaw, Christopher M. Hobot, Phillip Edward McDonald
-
Patent number: 8802131Abstract: Described here are devices, methods, and kits for treating sinusitis and related respiratory conditions by locally delivering active agents to the osteomeatal complex over a sustained period of time. The devices may be passively fixed within the osteomeatal complex and/or include one or more features that actively fix it within the osteomeatal complex. The devices may optionally include a portion that extends into a sinus ostium, sinus cavity, and/or the nasal passage to deliver an active agent.Type: GrantFiled: August 14, 2009Date of Patent: August 12, 2014Assignee: Intersect ENT, Inc.Inventors: Patrick A. Arensdorf, Danielle L. Biggs, Rodney Brenneman, David B. Downie, Donald J. Eaton, Thomas R. Tice
-
Patent number: 8740839Abstract: Described here are paranasal sinus devices for treating paranasal sinus conditions. The devices include a cavity member, ostial member, and nasal portion. One or more of the cavity member, ostial member, and nasal portion may deliver an active agent for sustained release to treat the paranasal sinus condition. Exemplary paranasal sinus conditions are sinus inflammation due to functional endoscopic sinus surgery (FESS) and rhinosinusitis.Type: GrantFiled: September 15, 2010Date of Patent: June 3, 2014Assignee: Intersect ENT, Inc.Inventors: Donald J. Eaton, Thomas R. Tice, David B. Downie, Patrick A. Arensdorf, Rodney A. Brenneman, Danielle L. Biggs
-
Patent number: 8535707Abstract: Described here are devices, methods, and kits for treating sinusitis and related respiratory conditions by locally delivering active agents to the osteomeatal complex over a sustained period of time. The devices may be passively fixed within the osteomeatal complex and/or include one or more features that actively fix it within the osteomeatal complex. The devices may optionally include a portion that extends into a sinus ostium, sinus cavity, and/or the nasal passage to deliver an active agent.Type: GrantFiled: July 9, 2007Date of Patent: September 17, 2013Assignee: Intersect ENT, Inc.Inventors: Patrick A. Arensdorf, Danielle L. Biggs, Rodney Brenneman, David B. Downie, Donald J. Eaton, Thomas R. Tice
-
Patent number: 8337454Abstract: Described here are paranasal sinus devices for treating paranasal sinus conditions. The devices include a cavity member, ostial member, and nasal portion. One or more of the cavity member, ostial member, and nasal portion may deliver an active agent for sustained release to treat the paranasal sinus condition. Exemplary paranasal sinus conditions are sinus inflammation due to functional endoscopic sinus surgery (FESS) and rhinosinusitis.Type: GrantFiled: May 7, 2009Date of Patent: December 25, 2012Assignee: Intersect ENT, Inc.Inventors: Donald J. Eaton, Thomas R. Tice, David B. Downie, Patrick A. Arensdorf, Rodney Brenneman, Danielle L. Biggs